For our October #radonc journal club we will discuss hypofractionated prostate radiation with daily doses > 2 Gray. What are the data, and how easy is it to change from conventional radiation? Our article from The Lancet Oncology is:
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Dearnaley D et al, Lancet Oncol 2016;17:1047-60
The article is free for download. For the supplement including the protocol, click here. Thank you to Isabel Lokody and The Lancet Oncology for allowing us to share this important clinical trial!
Dr. Rahul Tendulkar of Cleveland Clinic will join us to discuss at the live journal club Sunday October 16th at 11AM- 12PM Central Standard Time. We will start open chat 6 AM CST Saturday October 15th to include global participation. Update: we anticipate some of the authors may join use as well!
We will focus on the following topics:
T1. What is the rationale for hypofractionated radiation for prostate cancer?
T2. What were the aim and methods of this study?
T3a. What were the results, and how do they compare to contemporary outcomes?
T3b. Given the long natural history of prostate cancer, are 5 years of data enough to switch based upon CHHiP and other published trials?
T4. For doctors who want to make the transition to hypofractionated prostate radiation, what are the critical success factors to adoption?
Any suggestions? Leave a comment or tweet us at @Rad_Nation. And please join us this weekend!